{"preliminary_commentary":{"by_channel":{"x_thread":5,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NEOpredict","nct_id":"NCT04205552","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neopredict-nct04205552. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NEOpredict","arms":[{"description":"Nivolumab 2 cycles, every two weeks (q2w)\n\no Nivolumab 240 mg i.v. over 30 min","label":"Nivolumab","type":"EXPERIMENTAL"},{"description":"Nivolumab/Relatlimab (80 mg) 2 cycles, every two weeks (q2w)\n\n* Nivolumab 240 mg i.v. over 30 min\n* Relatlimab 80 mg i.v. over 30 min (within 30 min of nivolumab)","label":"Nivolumab/Relatlimab (80 mg)","type":"EXPERIMENTAL"},{"description":"Nivolumab/Relatlimab (240 mg) 2 cycles, every two weeks (q2w)\n\n* Nivolumab 240 mg i.v. over 30 min\n* Relatlimab 240 mg i.v. over 30 min (within 30 min of nivolumab)","label":"Nivolumab/Relatlimab (240 mg)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-11-27","type":"ACTUAL"},"conditions":["NSCLC Stage II","NSCLC, Stage IIIA","NSCLC, Stage I"],"enrollment":{"count":90,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab 10 MG/ML Intravenous Solution","otherNames":[],"type":"DRUG"},{"name":"Relatlimab 10 MG/ML Intravenous Solution","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-11","lead_sponsor":"University Hospital, Essen","official_title":"Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-11-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Feasibility of four weeks of preoperative immunotherapy with Nivolumab, Nivolumab plus Relatlimab (80 mg), and Nivolumab plus Relatlimab (240 mg)","timeFrame":"Within 43 days after first study medication"}],"references":[{"citation":"Schuler M, Cuppens K, Plones T, Wiesweg M, Du Pont B, Hegedus B, Koster J, Mairinger F, Darwiche K, Paschen A, Maes B, Vanbockrijck M, Lahnemann D, Zhao F, Hautzel H, Theegarten D, Hartemink K, Reis H, Baas P, Schramm A, Aigner C. Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nat Med. 2024 Jun;30(6):1602-1611. doi: 10.1038/s41591-024-02965-0. Epub 2024 Apr 30.","pmid":"38689060","type":"RESULT"}],"start_date":{"date":"2020-03-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients","url":"https://clinicaltrials.gov/study/NCT04205552"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neopredict-nct04205552"}